Cipla raises $170 million from first-ever GDR issue
Inidan drug maker prices deal at low end of tight range in wake of 63% share price surge this year.
IndiaÆs second largest drug maker in terms of sales, Cipla Ltd, has raised $170 million from its first ever sale of Global Depositary Receipts. The CLSA and Kotak Mahindra led deal is said to have met with reasonable demand despite a 63% surge in the share price already this year.
The sharp share price spike is also said to have caused price sensitivity, which resulted in a tight marketing range and small order book. The GDRs were sold to...
To continue reading, please login or register for free